Glucose-lowering treatments and COVID-19 mortality in T2DM

Nat Rev Endocrinol. 2021 Jul;17(7):387-388. doi: 10.1038/s41574-021-00509-x.

Abstract

The poor prognosis in patients with diabetes mellitus who contract COVID-19 urged physicians to question routine drug treatment for people with type 2 diabetes mellitus. What treatment should we prioritize? So far only observational studies are available, although complementary interventional studies are needed to address this issue.

Publication types

  • Comment

MeSH terms

  • Blood Glucose
  • COVID-19*
  • Diabetes Mellitus, Type 2* / drug therapy
  • England
  • Glucose
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Prescriptions
  • SARS-CoV-2

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Glucose